ABSTRACT
Introduction The linguistic factor may have delayed the universal adoption of the International Anatomical Terminology (IAT), which was widespread in Latin and in English only. Independent translations are possible, but they are not devoid of methodological difficulties. Objective To estimate the usage of the translated version of the Terminologia Anatomica in neurosurgical articles in Brazil. Method Consecutive national publications were checked for the correspondence of their anatomical terms to the following categories: IAT Brazilian version; IAT in Latin; Nomina Anatomica previous versions; incomplete terms; derivative terms; eponyms; neologisms; and others (misspellings and prosaic terms). The years 2014 and 2015 were chosen for analysis so that included articles were published at least 16 years after the publication of the original IAT (1998) and at least 13 years since the publication of the Brazilian version (2001). Results Out of a total of 183 articles analyzed, 1,132 anatomical terms were identified, referring to 334 different anatomical structures. Most of the structures were described using terms from the Brazilian version of the IAT (n » 834; 73.7%). Those that did not belong to or did not derive from any version of the IAT totaled 281 (24.8%). The remaining 17 terms (1.5%) corresponded to words derived or provided for in the Latin IAT. No association was identified between the number of authors and any category of nomenclature. Conclusion Althoughmost anatomical structures cited in Portuguese were described in accordance with the Brazilian version of the IAT, the degree of adherence was considered moderate given that about one-quarter of the terms escaped this terminology.
Subject(s)
Translating , Brazil , Anatomy , Neuroanatomy , Terminology as Topic , Chi-Square DistributionABSTRACT
The aim was to investigate if botulinum toxin type A (BTx-A) associated with physical therapy is superior to physical therapy alone in post stroke spasticity. A randomized, double-blinded controlled trial was performed in a rehabilitation unit on Northeastern, Brazil. Patients with post stroke spasticity were enrolled either to BTx-A injections and a pre-defined program of physical therapy or saline injections plus physical therapy. Primary endpoint was functional performance evaluated through time up and go test, six minutes walking test and Fugl-Meyer scale for upper limb. Secondary endpoint was spasticity improvement. Confidence interval was considered at 95%. Although there was a significant decrease in upper limbs flexor tonus (P<0.05) in the BTx-A group, there was no difference regarding functional performance after 9 months of treatment. When analyzing gait speed and performance, both groups showed a significant improvement in the third month of treatment, however it was not sustained over time. Although BTx-A shows superiority to improve muscle tone, physical therapy is the cornerstone to improve function in the upper limbs of post stroke patients.
ABSTRACT
A paraparesia espástica é caracterizada pela perda de função total ou parcial dos membros inferiores associado ao aumento do tônus muscular velocidade-dependente. A toxina botulínica é utilizada no tratamento de diversos padrões de espasticidade, sejam em flexão, extensão ou adução. Objetivo: determinar a eficácia e segurança do bloqueio químico com toxina botulínica em pacientes com paraparesia espástica. Método: foi realizada uma revisão sistemática com busca nas bases de dados do PUBMED, MEDLINE, LILACS e SCIELO. Os critérios de inclusão foram: ensaios clínicos que utilizaram a toxina botulínica para o tratamento de pacientes com paraparesia espástica e publicados em inglês a partir da década de 1980. Os desfechos considerados foram: a pontuação na Escala de Ashworth Modificada, a amplitude de movimento passiva e ativa e os efeitos adversos da toxina botulínica. Resultados: foram incluídos cinco artigos. Todos mostraram melhora da espasticidade nos pacientes estudados. Quatro artigos mostraram aumento da amplitude de movimento passivo e três relataram aumento da amplitude de movimento ativo. Três artigos trouxeram relatos de efeitos adversos após o uso da toxina botulínica, mas a maioria deles não eram graves e cessaram espontaneamente. Conclusão: os estudos analisados mostraram que a toxina botulínica é eficaz e segura em pacientes com paraparesia espástica.(AU)
Spastic paraparesis is the loss of total or partial lower limb function associated with increased speed-dependent muscle tone. Botulinum toxin is used in the treatment of several spasticity presentations that include flexion, extension and adduction. Objective: To determine both safety and efficacy of botulinum toxin as a blocking agent in the treatment of spastic paraparesis. Method:A systematic review was carried out with a search on PUBMED, MEDLINE, LILACS and SCIELO databases. The inclusion criteria were: clinical trials that used botulinum toxin for the treatment of patients with spastic paraparesis and published in English from the 1980s. The following outcomes were assessed by the studies: the Ashworth Modified scale score, the range of passive and active motion and botulinum toxin adverse effects. Results:Five articles were included. All of them showed spasticity improvements in the patients. Four studies showed increases in passive range of motion and three articles showed increase in active range of motion. Three papers reported adverse effects after botulinum toxin use but they were mostly mild and ceased spontaneously. Conclusion: Most analyzed studies indicated that botulinum toxin is safe and efficient inthe treatment of spastic paraparesis. (AU)
